Final Assessment and Report

PDF cover

Unsupported Price Increase Assessment: Final Assessment and Report

ICER’s final assessment and report.

NOTE: After initial publication of the Unsupported Price Increase Report, Genentech provided ICER with exact values for the net price of Rituxan in Q42016 and Q42018, and the volume sold in 2017 and 2018. Due to the discrepancy between the exact values and the data ICER obtained from SSR Health, LLC, ICER decided to update the report with the data provided by Genentech.



View All Materials on this Topic or Go Back to View More Materials